[HTML][HTML] Phytoestrogens in clinical practice: a review of the literature
CB Tempfer, EK Bentz, S Leodolter, G Tscherne… - Fertility and sterility, 2007 - Elsevier
OBJECTIVE: To review clinical studies assessing the effect of phytoestrogen
supplementation on the signs and symptoms of the climacteric syndrome and on the …
supplementation on the signs and symptoms of the climacteric syndrome and on the …
[HTML][HTML] Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
…, G Perez, DM Harper, S Leodolter… - … England Journal of …, 2007 - Mass Medical Soc
Background A phase 3 trial was conducted to evaluate the efficacy of a prophylactic
quadrivalent vaccine in preventing anogenital diseases associated with human …
quadrivalent vaccine in preventing anogenital diseases associated with human …
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a …
EA Joura, S Leodolter, M Hernandez-Avila… - The Lancet, 2007 - thelancet.com
Background Vulval and vaginal cancers among younger women are often related to
infection with human papillomavirus (HPV). These cancers are preceded by high-grade …
infection with human papillomavirus (HPV). These cancers are preceded by high-grade …
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine …
…, KA Ault, SM Garland, S Leodolter… - The Journal of …, 2009 - academic.oup.com
Abstract Background Human papillomavirus (HPV)–6/11/16/18 vaccine reduces the risk of
HPV-6/11/16/18–related cervical intraepithelial neoplasia (CIN) 1–3 or adenocarcinoma in …
HPV-6/11/16/18–related cervical intraepithelial neoplasia (CIN) 1–3 or adenocarcinoma in …
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women
…, KA Ault, SM Garland, S Leodolter… - Journal of the …, 2010 - academic.oup.com
Background The impact of the prophylactic vaccine against human papillomavirus (HPV)
types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was …
types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was …
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital …
…, P García, KA Ault, SM Garland, S Leodolter… - Cancer prevention …, 2009 - AACR
Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection
from HPV 6/11/16/18–related cervical, vaginal, and vulvar disease through 3 years. We …
from HPV 6/11/16/18–related cervical, vaginal, and vulvar disease through 3 years. We …
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine …
…, KA Ault, SM Garland, S Leodolter… - The Journal of …, 2009 - academic.oup.com
Background We evaluated the impact of a quadrivalent human papillomavirus (HPV)
vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35 …
vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35 …
Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women.
…, G Breitenecker, S Leodolter - The Journal of …, 2000 - europepmc.org
Objective To determine trends in the epidemiology of vulvar intraepithelial neoplasia (VIN)
and squamous cell carcinoma (SCC) of the vulva in a Central European sample during the …
and squamous cell carcinoma (SCC) of the vulva in a Central European sample during the …
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
…, EH Tay, P García, KA Ault, SM Garland, S Leodolter… - Vaccine, 2008 - Elsevier
The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be
mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV …
mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV …
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV …
…, P García, KA Ault, SM Garland, S Leodolter… - Human …, 2009 - Taylor & Francis
Objective In the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL®/SILGARD®)
clinical program, 73% of women aged 16-26 were naïve to all vaccine HPV types. In these …
clinical program, 73% of women aged 16-26 were naïve to all vaccine HPV types. In these …